Profile data is unavailable for this security.
About the company
JW (Cayman) Therapeutics Co Ltd is a company primarily engaged in research and development, manufacturing, and marketing of cellular immunotherapy products. The Company has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. The Company’s main product, Carteyva, is an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) cell immunotherapy product independently developed by the Company based on a CAR-T cell process platform of Juno (a Bristol Myers Squibb company). The Company mainly conducts its business in the domestic market.
- Revenue in HKD (TTM)200.67m
- Net income in HKD-697.27m
- Incorporated2017
- Employees292.00
- LocationJW (Cayman) Therapeutics Co LtdNo 225 Meisheng RoadPilot Free Trade Zone, 4f, Building 42SHANGHAI KY1-1104ChinaCHN
- Websitehttps://www.jwtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sirnaomics Ltd | 13.89m | -109.53m | 803.09m | 52.00 | -- | -- | -- | 57.80 | -1.33 | -1.33 | 0.161 | -0.3803 | 0.0637 | -- | -- | 201,367.50 | -36.30 | -80.21 | -216.85 | -100.49 | 67.44 | -- | -570.30 | -27,838.86 | -- | -8.20 | -- | -- | -- | -- | 34.70 | -- | -38.10 | -- |
| Sunho Biologics Inc | 0.00 | -92.67m | 987.00m | 128.00 | -- | 1.82 | -- | -- | -0.6141 | -0.6141 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -14.33 | -- | -15.84 | -- | -- | -- | -- | -- | 6.57 | -- | 0.1242 | -- | -- | -- | 39.74 | -- | -- | -- |
| JW (Cayman) Therapeutics Co Ltd | 200.67m | -697.27m | 999.54m | 292.00 | -- | 0.9739 | -- | 4.98 | -1.68 | -1.68 | 0.4837 | 2.46 | 0.1046 | 1.34 | 9.59 | 714,127.90 | -36.34 | -35.14 | -47.41 | -39.06 | 55.52 | -- | -347.47 | -898.77 | 1.45 | -1,808.42 | 0.2907 | -- | -8.99 | -- | 23.10 | -- | -32.98 | -- |
| Brii Biosciences Ltd | 0.00 | -424.14m | 1.13bn | 96.00 | -- | 0.3999 | -- | -- | -0.5827 | -0.5827 | 0.00 | 3.90 | 0.00 | -- | -- | 0.00 | -14.05 | -49.92 | -14.09 | -54.57 | -- | -- | -- | -12,750.27 | -- | -- | 0.003 | -- | -100.00 | -- | -190.66 | -- | -33.13 | -- |
| B&K Corp Ltd | 294.66k | -206.17m | 1.21bn | 100.00 | -- | 12.69 | -- | 4,108.84 | -1.75 | -1.75 | 0.0025 | 0.8111 | -- | -- | -- | -- | -- | -- | -- | -- | 92.34 | -- | -69,968.59 | -- | -- | -- | 0.0371 | -- | -44.70 | -- | -101.78 | -- | -- | -- |
| Kintor Pharmaceutical Ltd | 12.40m | -188.61m | 1.35bn | 136.00 | -- | 4.95 | -- | 108.58 | -0.4361 | -0.4361 | 0.0287 | 0.5449 | 0.0194 | 10.66 | 1.06 | 73,811.91 | -29.53 | -47.72 | -44.54 | -55.96 | -55.12 | -36.16 | -1,521.00 | -8,974.73 | 0.4222 | -33.76 | 0.2881 | -- | -- | -- | 85.36 | -- | -53.11 | -- |
| Wuhan YZY Biopharma Co Ltd | 163.70m | -88.10m | 1.40bn | 106.00 | -- | -- | -- | 8.57 | -0.4545 | -0.4545 | 0.8445 | -0.1598 | 0.5805 | 11.54 | 13.96 | 1,448,654.00 | -31.24 | -- | -133.35 | -- | 63.96 | -- | -53.82 | -- | 0.9019 | -24.38 | 1.21 | -- | -- | -- | 49.09 | -- | -- | -- |
| HighTide Therapeutics Inc | 0.00 | -328.71m | 1.52bn | 57.00 | -- | 3.84 | -- | -- | -0.727 | -0.727 | 0.00 | 0.6920 | 0.00 | -- | -- | 0.00 | -49.50 | -- | -63.55 | -- | -- | -- | -- | -- | -- | -- | 0.2129 | -- | -- | -- | 59.35 | -- | -- | -- |
| Immunotech Biopharm Ltd | 0.00 | -252.32m | 1.56bn | 173.00 | -- | -- | -- | -- | -0.4508 | -0.4508 | 0.00 | -0.2872 | 0.00 | -- | -- | 0.00 | -37.04 | -36.20 | -186.73 | -45.67 | -- | -- | -- | -- | 0.0712 | -6.63 | 1.48 | -- | -- | -- | 44.18 | -- | 5.95 | -- |
| Cloudbreak Pharma Inc | 78.15m | -326.91m | 1.98bn | 60.00 | -- | -- | -- | 25.35 | -0.3897 | -0.3897 | 0.0932 | -3.08 | -- | -- | -- | 1,532,275.00 | -- | -- | -- | -- | -- | -- | -418.33 | -- | -- | -- | 19.44 | -- | -- | -- | 23.40 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to JW (Cayman) Therapeutics Co Ltd's reporting currency: Hong Kong Dollar HKD
0.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 30 Nov 2025 | 1.23m | 0.30% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 346.00k | 0.08% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 78.25k | 0.02% |
| DFA Australia Ltd.as of 30 Nov 2025 | 2.83k | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 2025 | 5.00 | 0.00% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 0.00 | 0.00% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
